This report was first published by Endpoints News. To see the original version, click here
Merck KGaA has trimmed its R&D pipeline after a strategic review.
The German pharma has removed studies of two drugs it picked up from the SpringWorks Therapeutics buyout. As it stands, there are no other ongoing clinical trials from that purchase, although it could still have preclinical assets from SpringWorks that are yet to enter trials.
您已阅读18%（432字），剩余82%（1940字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。